Testosterone Replacement Therapy: The Complete 2026 Guide for Men and Women

Educational guide for research and informational purposes only. Not medical advice.

Testosterone replacement therapy is one of the most evidence-supported interventions in men's health — and one of the most misunderstood. The clinical literature on TRT is extensive, spanning decades of randomized controlled trials, longitudinal observational data, and mechanistic research. The confusion stems not from the science but from the gap between how TRT is practiced in academic endocrinology and how it's experienced by the men who need it most.

This is a complete reference for understanding testosterone physiology, who benefits from TRT, what the evidence says, how protocols work, and how to monitor them properly.

Testosterone Physiology — What It Controls

Testosterone is the primary androgenic hormone in males and a significant hormonal signal in females. It is produced primarily in testicular Leydig cells in men (95%) and adrenal glands and ovaries in women. Its synthesis is controlled by the hypothalamic-pituitary-gonadal (HPG) axis: GnRH from the hypothalamus triggers LH and FSH release from the pituitary; LH signals Leydig cells to synthesize testosterone from cholesterol.

Testosterone acts through androgen receptors (AR) expressed in virtually every tissue in the body. Its functions span:

• Muscle: Stimulates muscle protein synthesis (myofibrillar and sarcoplasmic), increases satellite cell proliferation, reduces protein degradation via IGF-1 upregulation
• Bone: Increases bone mineral density; low testosterone is a major driver of osteopenia and fracture risk in men
• Adipose tissue: Inhibits lipoprotein lipase (fat storage enzyme) and promotes lipolysis; low testosterone strongly associated with visceral fat accumulation
• Brain: Modulates dopaminergic signaling, motivation, libido, mood regulation, and cognitive function including spatial ability and working memory
• Cardiovascular: Modulates vascular smooth muscle tone, erythropoiesis, lipid metabolism, and cardiac function
• Metabolic: Improves insulin sensitivity; low testosterone is bidirectionally associated with type 2 diabetes and metabolic syndrome
• Sexual function: Primary driver of libido in both sexes; essential for erectile function (acts on penile smooth muscle and NO production)
• Red blood cell production: Stimulates EPO and erythroid progenitor differentiation — the basis for the hematocrit monitoring requirement

The Decline Problem — Why So Many Men Are Hypogonadal

Testosterone levels in men have declined significantly at a population level over the past 40 years — independent of aging. Studies comparing age-matched cohorts from the 1980s to 2000s show mean testosterone levels 15–25% lower in later cohorts. The causes are multifactorial: increased obesity rates, endocrine-disrupting chemical exposure, chronic stress, sleep deprivation, sedentary behavior, and ultra-processed food consumption all independently suppress testosterone.

The result: laboratory "normal" ranges encompass a population in which many men are below their individual optimum. A man with testosterone of 310 ng/dL is technically "normal" by most laboratory reference ranges but is likely experiencing clinically meaningful hypogonadal symptoms.

Symptoms of Low Testosterone

• Low libido and sexual dysfunction
• Fatigue and reduced energy, even with adequate sleep
• Reduced motivation, drive, and competitive spirit
• Depression, irritability, emotional flatness
• Reduced muscle mass and strength despite training
• Increased body fat, especially visceral
• Cognitive fog, reduced working memory
• Reduced bone density (often silent until fracture)
• Anemia (reduced red blood cell production)
• Hot flashes, reduced facial/body hair, testicular atrophy

Diagnosing Hypogonadism — What Labs Are Needed

Proper diagnosis requires more than a single total testosterone measurement:

• TRT Guide 2026: Testosterone Therapy for Men & Women (morning, fasted) — establish baseline; two measurements below threshold on separate days recommended before initiating treatment
• Free testosterone — calculated or directly measured; critical in men with high SHBG (high SHBG binds testosterone, reducing the bioavailable fraction)
• SHBG — sex hormone-binding globulin; determines how much testosterone is "free" and biologically active
• LH and FSH — distinguish primary hypogonadism (testicular failure: low T, high LH/FSH) from secondary hypogonadism (pituitary/hypothalamic: low T, low/normal LH/FSH)
• Estradiol — testosterone aromatizes to estradiol; both low and high estradiol cause symptoms; sensitive LC-MS/MS assay preferred in men
• Prolactin — elevated prolactin suppresses LH/GnRH; common and correctable cause of secondary hypogonadism
• Thyroid (TSH, free T3/T4) — thyroid dysfunction mimics hypogonadism and compounds it
• Complete metabolic panel, CBC, PSA (men 40+), lipids, hematocrit

TRT Options — Delivery Methods Compared

The Subcutaneous Injection Advantage

Subcutaneous (SC) injection of testosterone cypionate/enanthate has gained significant traction as an alternative to intramuscular (IM) injection. SC injection produces slightly slower absorption and lower peak concentration — resulting in more stable trough-to-peak ratios, reduced hematocrit stimulation, and equivalent clinical efficacy. For self-administering patients, SC is technically easier and less painful than IM.

Protocol Design — Dosing and Titration

Starting Protocol

• Testosterone cypionate or enanthate: 80–120mg per week, divided (40–60mg twice weekly SC or IM) is the most physiologically rational starting approach
• Twice-weekly dosing maintains more stable levels and reduces hematocrit stimulation compared to once-weekly
• Allow 6–8 weeks at stable dose before checking follow-up labs — time for steady-state to be reached
• Titrate based on follow-up total testosterone, free testosterone, estradiol, and hematocrit

Target Ranges

• Total testosterone: 600–900 ng/dL is a common optimization target (upper-middle of young adult reference range)
• Free testosterone: upper third of reference range for age
• Estradiol: 20–40 pg/mL (sensitive assay) in most men; some men tolerate and benefit from higher levels
• Hematocrit: maintain below 52%; intervention (dose reduction, therapeutic phlebotomy) if rising above this threshold

Estrogen Management

Aromatase converts testosterone to estradiol in adipose tissue, liver, and brain. Higher body fat = more aromatization. The decision to use an aromatase inhibitor (AI) should be based on actual estradiol labs — not prophylactically. Many men on TRT do not require AI. Symptoms of high estradiol (gynecomastia, water retention, emotional lability) should be confirmed by bloodwork before AI initiation.

If AI use is warranted: anastrozole 0.25–0.5mg twice weekly is a common starting point; over-suppression of estradiol causes joint pain, mood dysregulation, reduced libido, and cardiovascular risk — avoid suppressing to undetectable levels.

Fertility Considerations — hCG and Peptide Alternatives

Exogenous testosterone suppresses LH and FSH through negative feedback, which reduces intratesticular testosterone and halts spermatogenesis. For men who want to preserve fertility:

• hCG (human chorionic gonadotropin) — mimics LH; maintains intratesticular testosterone and testicular volume; 250–500 IU 2–3x per week alongside TRT
• Kisspeptin — upstream HPG axis activation; may restore pulsatile LH secretion; under active research for fertility-sparing hypogonadism treatment
• Clomiphene citrate (Clomid) — selective estrogen receptor modulator; blocks negative feedback at pituitary; increases endogenous LH, FSH, and testosterone; fertility-preserving alternative to TRT for secondary hypogonadism
• Enclomiphene — the active trans isomer of clomiphene; similar mechanism with fewer side effects; increases testosterone and LH without suppressing spermatogenesis

TRT in Women

Testosterone is not a male hormone — it's an essential hormone in women at lower concentrations. Women produce testosterone primarily in the ovaries and adrenal glands. Low testosterone in women contributes to:

• Low libido (HSDD) — the most evidence-supported indication
• Fatigue and reduced energy
• Reduced muscle mass and strength
• Mood dysregulation and reduced well-being
• Cognitive changes

Female TRT typically uses very low-dose testosterone cream or gel (0.5–2mg/day) — roughly 5–10% of male doses. Target free testosterone in the upper half of the female reference range. Monitoring for androgenic side effects (acne, hair loss, voice changes) with dose adjustment as needed.

Evidence Base — What the Clinical Trials Show

The TRAVERSE trial (2023, NEJM) — the largest cardiovascular safety trial of TRT ever conducted (5,246 men, 33-month follow-up) — found no increased risk of major adverse cardiovascular events (MACE) with testosterone therapy in hypogonadal men with pre-existing cardiovascular disease or risk factors. This addresses the primary historical safety concern about TRT.

Additional evidence:

• TESTOSTERONE TRIALS (TTrials, 2016–2018): 790 men ≥65 years; TRT improved sexual function, physical function, bone density, and anemia in symptomatic hypogonadal older men
• Meta-analyses consistently show TRT improves lean mass, reduces fat mass, improves insulin sensitivity, and improves quality of life markers in hypogonadal men
• Observational data from large European cohorts (EPIC, HUNT) show low testosterone is an independent predictor of all-cause mortality

Stack Integration — TRT and Peptides

TRT and peptide protocols are not competing approaches — they address different axes of the same hormonal optimization goal:

• TRT + CJC-1295/Ipamorelin — testosterone optimizes the androgen axis; GH secretagogues optimize the GH/IGF-1 axis; combined, they address both major anabolic hormonal systems
• TRT + BPC-157/TB-500 — testosterone supports muscle repair and protein synthesis; recovery peptides accelerate the local tissue healing process
• TRT + GLP-1 therapy — for men with both hypogonadism and significant excess fat; GLP-1 drives fat loss; TRT maintains muscle during deficit and addresses the low testosterone that excess adiposity drives

Getting Started

• Doctor's Consultation — first step before initiating any hormonal protocol; proper diagnosis and individualized protocol design
• Comprehensive Lab Panel — baseline bloodwork including testosterone, LH/FSH, estradiol, SHBG, thyroid, metabolic panel, CBC, lipids

References

1. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). N Engl J Med. 2023;389(2):107–117.
2. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715–1744. (Endocrine Society Guidelines)
3. Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (TTrials). N Engl J Med. 2016;374(7):611–624.
4. Travison TG, et al. A Population-Level Decline in Serum Testosterone Levels in American Men. J Clin Endocrinol Metab. 2007;92(1):196–202.
5. Davis SR, et al. Testosterone in Women — the Clinical Significance. Lancet Diabetes Endocrinol. 2015;3(12):980–992.

Educational Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any hormonal protocol.

FitAF Performance — Educational content only.